Clinical trials: Primary Erythromelalgia
Primary Erythromelalgia, Inherited Erythromelalgia
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
This is a Phase 2a single-center, randomized, double-blind, Placebo-controlled, parallel group study with XPF-002 applied twice daily over 14 or 21 days in patients with Primary/Inherited Erythromelalgia (IEM).
- Trial name
- NCT01486446
- Testing
- XPF-002
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Xenon Pharmaceuticals Inc.